Tagged with CTI

USA As healthcare costs are set to be a key issue for voters in the upcoming US presidential election, PhRMA’s Robert Zirkelbach lays out why policymakers must abandon partisan solutions that do not address underlying access and affordability issues. Instead, Zirkelbach urges for greater protection of the USA’s world-leading biopharmaceutical R&D…

USA The Pharmaceutical Research and Manufacturers of America (PhRMA) has had a board reshake, naming Gilead Sciences Chairman and CEO Daniel O’Day as its new chair. The reorganisation comes after the industry group’s failed efforts to block the Inflation Reduction Act (IRA) and the departure of several high-profile members.   Gilead…

USA As part of our Transformative 2023: Regional Pharma Trends report, PharmaBoardroom’s Louis Haynes takes a look at a watershed year for drug pricing in the planet’s most lucrative pharma market.   Drug development is inherently a risky business, but this will compound that risk further… to the point where now,…

Global Well-informed and data-driven healthcare decision making has never been more important. Healthcare systems across the world – in both developed and developing contexts – are grappling with the challenge of providing quality treatments and services to patients while ensuring that their money is well spent. At the forefront of helping…

USA The US Inflation Reduction Act (IRA) passed last year by the Biden administration and hotly contested by the innovative pharma industry, has started to look more like a reality since the first ten drugs subject to price negotiations under the IRA were announced in August. The negotiated prices will not…

USA PhRMA President and CEO Stephen J. Ubl takes aim at the health insurers and pharmacy benefit managers (PBMs) driving medicines costs up in the US, and the Inflation Reduction Act (IRA) which he sees as failing to address the patient affordability conundrum. Ubl calls for a policy framework able to…

USA With the passage of the US Inflation Reduction Act (IRA) that will begin to take effect this year, the biopharma industry continues to grapple with the implications of the new law while deciding how to move forward in response to it. At the recent BIO CEO and Investor Conference, stakeholders…

Global Antimicrobial resistance (AMR), or the resistance of pathogens to antibiotics, antivirals, antifungals and antiparasitics has been declared by the World Health Organization (WHO) as one of the top 10 global public health threats and was associated with the death of some 5 million people in 2019. The latest WHO report…

Africa While HIV has shifted from a death sentence to a manageable disease in most developed nations, there are several reasons why it still represents a huge global issue. It remains highly infectious and difficult to detect in the early stages of infection, while existing treatments are unavailable or too expensive…

France The latest news from French pharma, including fears of medicine shortages and suspension of online sales of paracetamol, CARMAT’s artificial heart product entering a study in France, Sanofi’s expanded deal with Innate Pharma and new funding for cell and gene therapy biotech Cellectis.   France suspends internet sales of paracetamol …

Singapore MSD is set to inject an additional USD 500 million into its existing Singapore manufacturing operations with two new facilities to produce vaccines and biologics. One of the new plants will turn out MSD’s immunotherapy for cancer and its human papillomavirus (HPV) vaccine for the Asia-Pacific region. The reason we…

USA Pharma companies have become vocal about social issues in recent years, championing access and affordability and launching initiatives to address diversity, but in the weeks since the United States’ Supreme Court’s overturn of the Roe v. Wade ruling on abortion the industry’s reaction has been far from consistent. While certain…